Gemphire Therapeutics Inc. 4
4 · Gemphire Therapeutics Inc. · Filed Mar 14, 2017
Insider Transaction Report
Form 4
Gullans Steven R. Ph.D.
Director
Transactions
- Purchase
Common Stock
2017-03-10$9.47/sh+52,798$499,997→ 858,823 total(indirect: Held by Excel Venture Fund II, L.P.) - Purchase
Warrant to Purchase Common Stock
2017-03-10$9.47/sh+39,599$375,003→ 39,599 total(indirect: Held by Excel Venture Fund II, L.P.)Exercise: $10.40From: 2017-03-10Exp: 2022-03-15→ Common Stock (39,599 underlying)
Footnotes (2)
- [F1]The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017.
- [F2]The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.